What is the translation of " REACTOGENICITY " in Slovenian?

• reaktogenost

Examples of using Reactogenicity in English and their translations into Slovenian

No data are available at present on reactogenicity after a second half adult i. e.
Trenutno ni podatkov o reaktogenosti po drugi uporabi polovičnega odmerkatj.

Reactogenicity was higher in children receiving whole cell pertussis vaccines concomitantly.
Reaktogenost je bila večja pri otrocih, ki so sočasno dobivali cepivo proti oslovskemu kašlju s celimi celicami.

In a clinical study that evaluated reactogenicity in children aged 6 to 35 months who received two half adult i. e.
V klinični študiji, s katero so ocenili reaktogenost pri otrocih, starih od 6 do 35 mesecev, ki so dobili dva polovičnatj.

Reactogenicity after a third dose, administered 12 months after the second dose, was higher than after both first and second dose.
Reaktogenost po tretjem odmerku, ki je bil dan 12 mesecev po drugem odmerku, je bila večja kot po prvem in drugem odmerku.

Those trials have shown that the safety and reactogenicity profile of the liquid formulation is comparable to the lyophilised formulation.
Ta preskušanja so pokazala, da je profil varnosti in neželenih učinkov tekoče oblike cepiva primerljiv s profilom liofilizirane oblike cepiva.

Reactogenicity after a third dose, administered 12 months following the first dose, was higher than after both first and second dose.
Reaktogenost po tretjem odmerku, danem 12 mesecev po prvem odmerku, je bila višja kot po obeh, prvem in drugem odmerku.

A clinical study(D-H5N1-009) evaluated the reactogenicity in children 3 to 5 and 6 to 9 years of age who received either two adult i. e.
S klinično študijo(D-H5N1-009) so ocenili reaktogenost pri otrocih, starih od 3 do 5 in od 6 do 9 let, ki so dobili v presledku 21 dni bodisi dva odmerka za odrasletj.

Two doses of IMVANEX given at a 7-day interval showed lower immune responses and slightly more local reactogenicity than two doses given at a 28-day interval.
Dva odmerka cepiva IMVANEX, dana v 7-dnevnem intervalu, sta pokazala nižje imunske odzive in nekoliko večjo lokalno reaktogenost, kot dva odmerka, dana v 28-dnevnem intervalu.

In a clinical study that evaluated reactogenicity in children 3 to 5 and 6 to 9 years of age who received a single half adult i. e.
V klinični študiji, s katero so ocenili reaktogenost pri otrocih, starih od 3 do 5 in od 6 do 9 let, ki so dobili en polovični odmerektj.

In the 12-14 months age group who received 2 doses of Nimenrix given 2 months apart, the first and second doses were associated with similar local and systemic reactogenicity.
V starostni skupini od 12 do 14 mesecev, ki je prejela 2 odmerka cepiva Nimenrix v presledku 2 mesecev, sta bila prvi in drugi odmerek povezana s podobnimi lokalnimi in sistemskimi reakcijami.

Regardless of age, reactogenicity was higher after the first dose than after the second vaccination.
Reaktogenost po tretjem odmerku, ki je bil dan 12 mesecev po drugem odmerku, je bila večja kot po prvem in drugem odmerku..

Data in children and adolescents 3-17 years suggest a slight decrease in reactogenicity after the second dose, with no increase in rates of fever.
Podatki pri otrocih in mladostnikih, starih med 3-17 let, kažejo na majhno znižanje reaktogenosti po drugem odmerku, brez zvišanja stopnje zvišane telesne temperature.

The reactogenicity profile of Fendrix in healthy subjects was generally comparable to that seen in pre- haemodialysis and haemodialysis patients.
Reaktogeni profil cepiva Fendrix pri zdravih osebah je bil na splošno primerljiv s tistim pri predhemodializnih in hemodializnih bolnikih.

In a study, in 300 subjects aged from 12 years up to and including 15 years, the reactogenicity profile of Ambirix was compared to that of the three-dose combined vaccine.
V študiji so pri 300 osebah, starih od 12 do vključno 15 let, primerjali pojavnost neželenih učinkov po cepljenju s cepivom Ambirix in pojavnost neželenih učinkov po prejemu treh odmerkov kombiniranega cepiva.

The reactogenicity profile and rates of adverse events among subjects aged 56-65 years who received Menveo(N=216), were similar to that observed in Menveo recipients subjects aged 11-55.
Profil reaktogenosti in stopnje neželenih učinkov med osebami, starimi med 56-65 leti, ki so dobili cepivo Menveo(n= 216) so bile podobne tistim, ki so jih opazili pri osebah, cepljenih s cepivom Menveo, starih med 11-55 let.

The approval was based on results from clinical trials, which investigated the immunogenicity and reactogenicity of Hexavac when administered according to specific primary and booster vaccination schedules.
Odobritev je temeljila na kliničnih preizkušanjih, v katerih so raziskovali imunogenost in reaktogenost zdravila Hexavac, kadar se ga daje v skladu z določeno shemo osnovnega in obnovitnega cepljenja.

Clinical trials involving the administration of 2,476 doses of Fendrix to 82 pre-haemodialysis and haemodialysis patients and to 713 healthy subjects 15 years of age allowed to document the reactogenicity of the vaccine.
V kliničnih preskušanjih je bilo z 2.476 odmerki cepiva Fendrix cepljenih 82 predhemodializnih in hemodializnih bolnikov ter 713 zdravih oseb, ki so bile stare 15 let ali več, kar je omogočilo dokumentirati reaktogenost cepiva.

The administration of a second half adult or an adult dose did not enhance the reactogenicity, except for rates of general symptoms which were higher after the second dose, particularly for rates of fever in< 6 year olds.
Uporaba drugega polovičnega odmerka za odrasle ali polnega odmerka za odrasle ni povečala reaktogenosti, razen stopenj splošnih simptomov, ki so bile višje po drugem odmerku, zlasti kar zadeva deleže zvišane telesne temperature pri mlajših od 6 let.

Reactogenicity was also evaluated in healthy adults aged 18-60 years who received a first 0.5 ml dose of either Arepanrix(H1N1)(N=167) or an AS03-containing vaccine containing HA from H1N1v manufactured using a different process(N=167).
Reaktogenost so ocenili tudi pri zdravih odraslih, starih od 18 do 60 let, ki so kot prvi 0,5-ml odmerek cepiva dobili bodisi Arepanrix(H1N1)(n= 167) bodisi cepivo z AS03, z vsebnostjo HA iz H1N1v, pridobljeno z drugačnim postopkom(n= 167).

As an identified risk, an appropriate warning should be included in section 4.4. Moreover section 4.8 should be revised to reflect reactogenicity data from the three paediatric studies D-Pan H5N1-009, -013 and 032.
Glede na ugotovljeno tveganje je treba ustrezno opozorilo vključiti v poglavje 4.4. Poleg tega je treba poglavje 4.8 revidirati tako, da bo odražalo podatke o reaktogenosti, zbrane v treh pediatričnih študijah D-Pan H5N1-009, -013 in 032.

In clinical studies that evaluated the reactogenicity in children 10 to 17 years of age who received either two 0.5 ml doses(adult dose) or two 0.25 ml doses(half adult dose)(21 days apart) of Pandemrix(H1N1)v, the per-dose frequency of the following adverse reactions was as shown in the table:.
V kliničnih študijah, s katerimi so ocenili reaktogenost pri otrocih, starih od 10 do 17 let, ki so dobili ali dva 0,5 ml odmerka(odmerek za odrasle) ali dva 0,25 ml odmerka(polovični odmerek za odrasle)(21 dni narazen) cepiva Pandemrix (H1N1)v, je bila pogostnost naslednjih neželenih učinkov na odmerek, kot je prikazano v preglednici:.

Data obtained with the mock-up vaccine will support a vaccination strategy that is likely to be used for the pandemic vaccine: clinical immunogenicity, safety and reactogenicity data obtained with mock-up vaccines are relevant for the pandemic vaccines.
Podatki, dobljeni z modelnim cepivom, bodo podpirali strategijo cepljenja, ki bo verjetno uporabljena za pandemsko cepivo: podatki o klinični imunogenosti, varnosti in reaktogenosti, pridobljeni z modelnimi cepivi, so pomembni za pandemska cepiva.

In order to further investigate the safety and reactogenicity of Pandemic influenza vaccine H5N1 MedImmune, the MAH should conduct an open-label single arm interventional study to evaluate the safety and immunogenicity of P/LAIV in children and adolescents from 12 months to less than 18 years of age during the next declared pandemic.
Za dodatno proučitev varnosti in reaktogenosti Cepiva proti pandemski gripi H5N1 MedImmune mora imetnik dovoljenja za promet z zdravilom med naslednjo razglašeno pandemijo opraviti odprto intervencijsko študijo z eno skupino(enim krakom) za oceno varnosti in imunogenosti P/LAIV pri otrocih in mladostnikih, starih od 12 mesecev do manj kot 18 let.

Data obtained with the mock-up vaccine will support a vaccination strategy that is likely to be used for the pandemic vaccine: clinical immunogenicity, safety and reactogenicity data obtained with mock-up vaccines are relevant for the pandemic vaccines.
Podatki, pridobljeni z uporabo modelnega cepiva, bodo uporabljeni pri oblikovanju strategije cepljenja, ki bo najverjetneje uporabljena za cepivo proti pandemski gripi: podatki o klinični imunogenosti, varnosti in reaktogenosti, pridobljeni z modelnimi cepivi, veljajo tudi za pandemska cepiva.

In clinical studies that evaluated reactogenicity in adults aged 18 years and above who received two 0.5 ml doses of Pandemrix(H1N1)v, higher rates of general solicited symptoms(such as fatigue, headache, arthralgia, myalgia, shivering, sweating and fever) were observed after the second dose compared to the first dose.
V kliničnih študijah, s katerimi so ocenili reaktogenost pri zdravih odraslih, starih 18 ali več, ki so dobili dva 0,5 ml odmerka cepiva Pandemrix (H1N1)v, so bili deleži splošnih simptomov, ki so bili spodbujeno poročani(npr. utrujenost, glavobol, artralgija, mialgija, drgetanje, znojenje in zvišana telesna temperatura), po drugem odmerku večji kot po prvem odmerku.

Data obtained with the H5N1 vaccines will support a vaccination strategy that is likely to be used for the pandemic vaccine: clinical immunogenicity, safety and reactogenicity data obtained with H5N1 vaccines are relevant for the pandemic and prepandemic vaccines.
Podatki, pridobljeni z uporabo cepiv proti H5N1, bodo uporabljeni pri oblikovanju strategije cepljenja, ki bo najverjetneje uporabljena za cepivo proti pandemski gripi: podatki o klinični imunogenosti, varnosti in reaktogenosti, pridobljeni s cepivi proti H5N1, veljajo tudi za pandemska in predpandemska cepiva.

Local reactogenicity of primary vaccination course was similar in infants< 12 months of age and in children> 12 months of age except for injection site pain for which the incidence increased with increasing age: pain was reported by more than 39% of the infants< 12 months of age and by more than 58% of the children> 12 months of age.
Lokalna reaktogenost po primarnem cepljenju je bila pri dojenčkih, mlajših od 12 mesecev, podobna kot pri otrocih, starejših od 12 mesecev, razen glede bolečin na mestu injiciranja; njihova incidenca se je povečevala z naraščajočo starostjo: bolečine so bile navedene pri več kot 39% dojenčkih, mlajših od 12 mesecev, in pri več kot 58% otrocih, starejših od 12 mesecev.